"With all the Positive vibes why are we where we are?"

Telepanel, it is exactly those types of repeated questions that have already been answered or cannot be answered that resulted in SanFran getting banned. In addition to ARR's great response to you, many others have answered this in previous posts. I will not re-hash those responses here. My own take is that the uncertainty exceeds the potential in the eyes of many investors. From a clinical development standpoint, apabetalone is still a successful phase 3 trial away from approval. So there is a time factor too. The break through therapy designation is great, but this does not make up for the failure to meet the primary endpoint in BETonMACE. The Options 1-3 going forward are encouraging, but these are plans not guarantees. If and when some of these promises come to fruition, then I think it's a whole new ball game. 

BDAZ